Gretai:4147

TaiMed Announces Significant Progress in Clinical Trials for New HIV Treatment

Company champions long-acting HIV therapy with new biologic drug TMB-365/380 combination; after favorable results of Phase1b/2a, company plans to accelerate Phase 2 clincial study to expedite path to market TAIPEI, Oct. 16, 2023 /PRNewswire/ -- TaiMed Biologics

2023-10-16 21:00 1435